Adverse effects of ketoconazole in dogs - A retrospective study (Veterinary Dermatology (2008) 19, 4, (199-208) DOI: 10.1111/j.1365-3164.2008.00675.x);Adverse effects of ketoconazole in dogs ? A retrospective study

Veterinary Dermatology

Volumn 19, Issue 4, 2008, Pages 199-208

  Mayer, Ursula K ^a   Glos, Katharina ^a   Schmid, Matthias ^a,e   Power, Helen T ^b   Bettenay, Sonya V ^c,d   Mueller, Ralf S ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Dermatology for Animals   (United States)

^c Animal Skin and Allergy Clinic   (Australia)

^d Tierdermatologie Deisenhofen   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

ANTIFUNGAL AGENT; KETOCONAZOLE;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DOG; DOG DISEASE; FEMALE; MALE; RETROSPECTIVE STUDY;

ANIMALS; ANTIFUNGAL AGENTS; DOG DISEASES; DOGS; FEMALE; KETOCONAZOLE; MALE; RETROSPECTIVE STUDIES;

EID: 58149383181     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2008.00705.x     Document Type: Erratum

References (47)

1. De Jaham C, Paradis M, Papich MG. Antifungal dermatologic agents: azoles and allylamines. Compendium on Continuing Education for the Practicing Veterinarian Small Animal 2000; 22: 548-59.
2. Toboada J, Grooters AM. Systemic Antifungal Therapy. London: Saunders, 2002: 149-62.
3. Scott DW, Miller WH, Griffin CE. Muller and Kirk's Small Animal Dermatology. Philadelphia, PA: Saunders, 2001: 336-422.
4. Sonino N. The use of ketoconazole as an inhibitor of steroid production. New England Journal of Medicine 1987; 317: 812-8.
5. Bruyette DS, Feldman EC. Ketoconazole and its use in the management of canine Cushing's disease. Compendium on Continuing Education for the Practicing Veterinarian Small Animal 1988; 10: 1379-85.
6. O'Neill T, Edwards GA, Holloway S. Efficacy of combined cyclosporine A and ketoconazole treatment of anal furunculosis. Journal of Small Animal Practice 2004; 45: 238-43.
7. Dahlinger J, Gregory C, Bea J. Effect of ketoconazole on cyclosporine dose in healthy dogs. Veterinary Surgery 1998; 27: 64-8.
8. Myre SA, Schoeder TJ, Grund VR et al. Critical ketoconazole dosage range for ciclosporin clearance inhibition in the dog. Pharmacology 1991; 43: 233-41.
9. D'Ambrosio C, Gallo C, Agresti A. II ketoconazolo nella terapia della leishmaniosi del cane. Atti SISVET 1986; 40: 492-6
10. Vanden Bossche H, Marichal P, Gorrens J, Coene MC. Biochemical basis for the activity and selectivity of oral antifungal drugs. British Journal of Clinical Practice Supplements 1990; 71: 41-6.
11. Rowan-Kelly B, Ferrante A, Thong YH. Modification of polymorphonuclear leucocyte function by imidazoles. International Journal of Immunopharmacology 1984; 6: 389-93.
12. Van Cutsem J, Van Gerven F, Cauwenbergh G, Odds F, Janssen PA. The antiinflammatory effects of ketoconazole. A comparative study with hydrocortisone acetate in a model using living and killed Staphylococcus aureus on the skin of guinea-pigs. Journal of the American Academy of Dermatology 1991; 25: 257-61.
13. Plumb DC. Veterinary Drug Handbook. White Bear Lake, MN: Pharma Vet Publishing, 1991; 431-6.
14. Hill P, Moriello KA, Shaw S. A review of systemic antifungal agents. Veterinary Dermatology 1995; 6: 59-66.
15. Heit MC, Riviere JE. Antifungal therapy: ketoconazole and otherazole derivatives. Compendium on Continuing Education for the Practicing Veterinarian Small Animal 1995; 1: 21-31.
16. Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clinical Pharmacology 2001; 1: 3.
17. Alderman C, Naranjo ADR. Probability scale. RGH Pharmacy E-Bulletin 2006; 20: 11.
18. Arimone Y, Begaud B, Miremont-Salame G et al. A new method for assessing drug causation provided agreement with experts? judgment. Journal of Clinical Epidemiology 2006; 59: 308-14.
19. Bennett JE. Antimicrobial agents: antifungal agents. In: Hardman JG, Goodman LS, Gilman A, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1995; 1180-2.
20. Knight TE, Shikuma CY, Knight J. Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. Journal of the American Academy of Dermatology 1991; 25: 398-400.
21. Janssen PA, Symoens JE. Hepatic reactions during ketoconazole treatment. American Journal of Medicine 1983; 74: 80-5.
22. Green CE. Antifungal chemotherapy. In: Green CE, eds. Infectious Diseases of the Dog and Cat. Philadelphia, PA: WB Saunders, 2006: 542-50.
23. Moriello KA. Ketoconazole: clinical pharmacology and therapeutic recommendations. Journal of the American Veterinary Medical Association 1986; 188: 303-6.
24. Muse R. Malassezia dermatitis. In: Bonagura WB, ed. Kirk's Current Veterinary Therapy. Philadelphia, PA: WB Saunders, 2000: 574-80.
25. Papich MG, Heit MC, Riviere JE. Antifungal and antiviral drugs. In: Adams RH, ed. Veterinary Pharmacology and Therapeutics. Ames, IA: Iowa State University Press, 2001: 918-46.
26. de Costa PD, Merideth RE, Sigler RL. Cataracts in dogs after long-term ketoconazole therapy. Veterinary Compendium of Ophthalmology 1995; 6: 176-80.
27. Levine HB. Ketoconazole in the Management of Fungal Disease. Sydney, NSW: ADIS Press, 1982: 39-72.
28. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. Journal of the American Academy of Dermatology 1994; 30: 677-98.
29. Mason K. Cutaneous malassezia. In: Griffin CE, Kwochka KW, MacDonald JM, eds. Current Veterinary Dermatology. The Science and Art of Therapy. St Louis, MO: Mosby, 1993: 45-53.
30. Brusko CS, Marten JT. Ketoconazole hepatotoxicity in a patient treated for environmental illness and systemic candidiasis. Drug Intelligence & Clinical Pharmacy 1991; 25: 1321-5.
31. Deutsch PH, Quintiliani R. Ketoconazole. Connecticut Medicine 1984; 48: 216-21.
32. Jones HE. Ketoconazole. Archives of Dermatology 1982; 118: 217-9.
33. Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, Avery GS. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982; 23: 1-36.
34. Smith EB, Henry JC. Ketoconazole: an orally effective antifungal agent. Mechanism of action, pharmacology, clinical efficacy and adverse effects. Pharmacotherapy 1984; 4: 199-204.
35. Shapiro LE, Knowles SR, Shear NH. Drug interactions. In: Bolognia JL, Jorizz JL, Rapini RP, eds. Dermatology. London: Mosby, 2003: 2085-99.
36. Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition 1995; 23: 154-8.
37. Kuroha M, Kuze Y, Shimoda M, Kokue E. In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. American Journal of Veterinary Research 2002; 63: 900-5.
38. Picard N, Djebli N, Sauvage FL, Marquet P. Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metabolism and Disposition 2007; 35: 350-5.
39. Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica 1998; 28: 313-21.
40. Guengerich FP. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chemico-Biological Interactions 1997; 106: 161-82.
41. Kukanich B, Lascelles BD, Aman AM, Mealey KL, Papich MG. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. Journal of Veterinary Pharmacology and Therapeutics 2005; 28: 461-6.
42. Taub ME, Podila L, Ely D, Almeida I. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metabolism and Disposition 2005; 33: 1679-87.
43. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrobial Agents and Chemotherapy 2002; 46: 160-5.
44. Brunton LL, Lazo JS, Parker KL. Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw Hill, 2006: 1180-2.
45. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. Journal of the American Academy of Dermatology 1993; 29: S50-4.
46. Ah-Sing E, Poole TW, Loannides C, King LJ. Mechanism of the ketoconazole'cyclosporin interaction. Archives of Toxicology 1990; 64: 511-3.
47. Pichard L, Fabre I, Fabre G et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metabolism and Disposition 1990; 18: 595-606.